Cue Biopharma Presents Positive Data Update from Ongoing Phase 1 Trials of CUE-101 for Recurrent/Metastatic HPV+ Head and Neck Squamous Cell Carcinoma at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
May 25, 2023 17:00 ET
|
Cue Biopharma, Inc.
As of the data cutoff date, nine of the 14 evaluable patients treated with CUE-101+ KEYTRUDA® (pembrolizumab) demonstrated tumor regression, with five confirmed partial responses (PRs) and three...
Cue Biopharma to Present at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
May 15, 2023 08:00 ET
|
Cue Biopharma, Inc.
Company to host Investor Update call on June 14, 2023 to review and discuss the clinical progress and associated data presented at ASCO BOSTON, May 15, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma,...
Cue Biopharma Reports First Quarter 2023 Financial Results and Recent Business Highlights
May 09, 2023 16:35 ET
|
Cue Biopharma, Inc.
BOSTON, May 09, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and...
Cue Biopharma to Present at the Upcoming JMP Securities Life Sciences Conference
May 08, 2023 08:00 ET
|
Cue Biopharma, Inc.
BOSTON, May 08, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and...
Cue Biopharma Welcomes Seasoned Pharmaceutical Executive Pamela D. Garzone, Ph.D., to its Board of Directors
April 25, 2023 08:00 ET
|
Cue Biopharma, Inc.
BOSTON, April 25, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and...
Cue Biopharma Welcomes Industry Veteran Mr. Patrick Verheyen to its Board of Directors
April 12, 2023 08:00 ET
|
Cue Biopharma, Inc.
BOSTON, April 12, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and...
Cue Biopharma Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights
March 21, 2023 16:10 ET
|
Cue Biopharma, Inc.
Received U.S. Food and Drug Administration (FDA) acceptance of Investigational New Drug (IND) application for CUE-102 in Wilms’ Tumor 1 (WT1)-expressing cancers and initiated dosing in a Phase 1 dose...
Cue Biopharma to Host Business Update Call and Webcast
March 15, 2023 08:00 ET
|
Cue Biopharma, Inc.
BOSTON, March 15, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and...
Cue Biopharma to Present at Two March 2023 Investor Healthcare Conferences
March 01, 2023 08:00 ET
|
Cue Biopharma, Inc.
BOSTON, March 01, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and...
Cue Biopharma Enters into a Strategic Collaboration and Option Agreement with Ono Pharmaceutical for CUE-401
February 22, 2023 08:00 ET
|
Cue Biopharma, Inc.
BOSTON, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and...